Literature DB >> 4280019

Dopamine agonist and antagonist activities of piribedil (ET495)and its metabolites.

B Costall, R J Naylor.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4280019     DOI： 10.1007/bf00499528

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN： 0028-1298            Impact factor:   3.000


× No keyword cloud information.
  17 in total

1.  Evidence for a new type of dopamine receptor stimulating agent.

Authors:  H Corrodi; K Fuxe; U Ungerstedt
Journal:  J Pharm Pharmacol       Date:  1971-12       Impact factor: 3.765

2.  The site and mode of action of ET495 for the mediation of stereotyped behaviour in the rat.

Authors:  B Costall; R J Naylor
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1973       Impact factor: 3.000

3.  Specific asymmetric behavior induced by the direct chemical stimulation of neostriatal dopaminergic mechanisms.

Authors:  B Costall; R J Naylor
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

4.  Extrapyramidal and mesolimbic involvement with the stereotypic activity of D- and L-amphetamine.

Authors:  B Costall; R J Naylor
Journal:  Eur J Pharmacol       Date:  1974-02       Impact factor: 4.432

5.  Neuroleptic and non-neuroleptic catalepsy.

Authors:  B Costall; R J Naylor
Journal:  Arzneimittelforschung       Date:  1973-05

6.  The role of telencephalic dopaminergic systems in the mediation of apomorphine-stereotyped behaviour.

Authors:  B Costall; R J Naylor
Journal:  Eur J Pharmacol       Date:  1973-10       Impact factor: 4.432

7.  ET495 and brain catecholamine mechanisms: evidence for stimulation of dopamine receptors.

Authors:  H Corrodi; L O Farnebo; K Fuxe; B Hamberger; U Ungerstedt
Journal:  Eur J Pharmacol       Date:  1972-11       Impact factor: 4.432

8.  Effect of a striatal spreading depression on the pharmacogenic catatonia.

Authors:  G Stille; A Sayers
Journal:  Int J Neuropharmacol       Date:  1969-03

9.  Letter: Preliminary investigation of the metabolism of piribedil (ET 495); a new central dopaminergic agonist and potential anti-parkinson agent.

Authors:  P Jenner; A R Taylor; D B Campbell
Journal:  J Pharm Pharmacol       Date:  1973-09       Impact factor: 3.765

10.  The involvement of dopaminergic systems with the stereotyped behaviour patterns induced by methylphenidate.

Authors:  B Costall; R J Naylor
Journal:  J Pharm Pharmacol       Date:  1974-01       Impact factor: 3.765
View more
  5 in total

1.  Solid-phase extraction of piribedil and its metabolites from plasma and urine without and after deconjugation, by high performance liquid chromatography.

Authors:  S Sarati; S Caccia
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Jul-Sep       Impact factor: 2.441

2.  A new central direct dopaminergic stimulant: 1-(Coumaran-5-yl methyl)-4-(2-thiazolyl) piperazine hydrochloride (S 3608).

Authors:  J C Poignant; H Gressier; M Petitjean; G Regnier; R Canevari
Journal:  Experientia       Date:  1975-10-15

3.  Opposing effects of dopaminergic to cholinergic compounds on a cerebral dopamine-activated adenylate cyclase.

Authors:  L C Tang; G C Cotzias
Journal:  Proc Natl Acad Sci U S A       Date:  1977-02       Impact factor: 11.205

4.  Kinetics of piribedil and effects on dopamine metabolism: hepatic biotransformation is not a determinant of its dopaminergic action in rats.

Authors:  S Sarati; G Guiso; S Garattini; S Caccia
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

5.  Action of neuroleptics and antidepressants on the hypothermia produced by dopaminomimetics apomorphine and piribedil in mice.

Authors:  E L Schelkunov
Journal:  J Neural Transm       Date:  1980       Impact factor: 3.575
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.